|
|
|
|
|
Value of Preoperative Lactate Dehydrogenase-to-Albumin Ratio Combined with AFP in Evaluating Prognosis of Patients with Hepatocellular Carcinoma |
| ZHOU Yongjie1, WANG Zhengfeng2, YAN Jun2, WANG Haiping3, XU Wen4, ZHOU Wence2 |
| 1. The First School of Clinical Medical College of Lanzhou University, Lanzhou 730000, China; 2. Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730000, China; 3. Key Laboratory of Biotherapy and Regenerative Medicine of Gansu Province, Lanzhou 730000, China; 4. Department of Otolaryngology Head and Neck Surgery, The First Hospital of Lanzhou University, Lanzhou 730000, China |
|
|
|
|
Abstract Objective To explore the value of preoperative LAR combined with AFP in evaluating the prognosis of patients with HCC. Methods We retrospectively analyzed the clinical data of 106 patients with HCC. Kaplan-Meier method was used to draw the survival curve. Univariate analysis was used to analyze possible variables affecting LAR. Cox risk regression model was used to evaluate the clinical value of preoperative LAR and AFP on the prognosis of HCC patients. Results The DFS and OS of the high LAR group and the high AFP group were shorter than those of the low LAR group and the low AFP group (P<0.05). LAR≥4.58, AFP≥400μg/L and T3-T4 were independent risk factors affecting DFS and OS of HCC patients (P<0.05). Postoperative interventional surgery was an independent factor influencing OS prolongation (P<0.05). The DFS and OS were the shortest in the high LAR and high AFP group, and the DFS and OS were the longest in the low LAR and low AFP group (P<0.05). Conclusion Preoperative LAR and AFP are independent poor prognostic factors of HCC. Preoperative LAR combined with AFP has a certain value in judging the prognosis of HCC patients.
|
| Keywords
Hepatocellular carcinoma
Lactate dehydrogenase
Albumin
Alpha-fetoprotein
Prognosis
|
|
|
|
Issue Date: 15 April 2022
|
|
[1] 中华预防医学会肝胆胰疾病预防与控制专业委员会, 中国研究
型医院学会肝病专业委员会, 中华医学会肝病学分会, 等. 原
发性肝癌的分层筛查与监测指南(2020版)[J]. 中华肿瘤防治杂
志, 2021, 28(2): 83-99. [Professional Committee for Prevention
and Control of Hepatobiliary and Pancreatic Disease of Chinese
Preventive Medicine Association, Professional Committee for
Hepatology, Chinese Research Hospital Association, Chinese
Society of Hepatology, Chinese Medical Association, et al.
Guideline for stratified screening and surveillance of primary liver
cancer(2020 Edition)[J]. Zhonghua Zhong Liu Fang Zhi Yan Jiu,
2021, 28(2): 83-99.]
[2] 刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J]. 肿瘤综
合治疗电子杂志, 2021, 7(2): 1-13. [Liu ZC, Li ZX, Zhang Y, et al.
Interpretation on the report of Global Cancer Statistics 2020[J].
Zhong Liu Zong He Zhi Liao Dian Zi Za Zhi, 2021, 7(2): 1-13.]
[3] Craig AJ, von Felden J, Garcia-Lezana T, et al. Tumour evolution
in hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol,
2020, 17(3): 139-152.
[4] Wang X, Mao M, He Z, et al. Development and Validation
of a Prognostic Nomogram in AFP-negativehepatocellular
carcinoma[J]. Int J Biol Sci, 2019, 15(1): 221-228.
[5] Aday U, Tatli F, Akpulat FV, et al. Prognostic significance of
pretreatment serum lactatedehydrogenase-to-albumin ratio in
gastric cancer[J].Contemp Oncol (Pozn), 2020, 24(3): 145-149.
[6] Gan W, Zhang MX, Wang JX, et al. Prognostic impact of lactic
dehydrogenase to albumin ratio in hepatocellular carcinoma
patients with Child-PughⅠwho underwent curative resection:
a prognostic nomogram study[J]. Cancer Manag Res, 2018, 10:
5383-5394.
[7] 付蕾, 李潜, 卢创新, 等. 尿酸联合CA199检测对结直肠癌TNM
分期和预后判断的价值[J]. 肿瘤, 2020, 40(7): 496-502. [Fu L, Li
Q, Lu CX, et al. The value of combined detection of uric acid and
CA199 in TNM stage and prognosis of patients with colorectal
cancer[J]. Zhong Liu, 2020, 40(7): 496-502.]
[8] 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况
分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28. [Zheng RS, Sun
KX, Zhang SW, et al. Report of cancer epidemiology in China,
2015[J]. Zhonghua Zhong Liu Za Zhi, 2019, 41(1): 19-28.]
[9] Feng RM, Zong YN, Cao SM, et al. Current cancer situation
in China good or bad news from the 2018 GlobalCancer
Statistics?[J]. Cancer Commun (Lond), 2019, 39(1): 22.
[10] Aday U, B?yük A, Akkoc H. The prognostic significance of serum
lactate dehydrogenase-to-albumin ratio in colorectal cancer[J].
Ann Surg Treat Res, 2020, 99(3): 161-170.
[11] Feng JF, Wang L, Yang X, et al. Prognostic value of lactate
dehydrogenase to albumin ratio (LAR) in patients with resectable
esophageal squamous cell carcinoma[J]. Cancer Manag Res,
2019, 11: 7243-7251.
[12] 丘金梅, 龚娟, 谢青池, 等. 乳酸脱氢酶在肿瘤代谢中的作用
及以其为靶标的抗肿瘤药物研发[J]. 肿瘤防治研究, 2020,
47(12): 980-985. [Qiu JM, Gong J, Xie QC, et al. Role of Lactate
Dehydrogenase in Tumor Metabolism and Progress of LDHtargeted
Drugs[J]. Zhong Liu Fang Zhi Yan Jiu, 2020, 47(12):
980-985.]
[13] Gao S, Wu M, Chen Y, et al. Lactic dehydrogenase to albumin
ratio in prediction of unresectable pancreatic cancer with
intervention chemotherapy[J]. Future Oncol, 2018, 14(14):
1377-1386.
[14] Wu SJ, Lin YX, Ye H, et al. Prognostic value of alkaline
phosphatase, gamma-glutamyl transpeptidase andlactate
dehydrogenase in hepatocellular carcinoma patients treated with
liver resection[J]. Int J Surg, 2016, 36(PtA): 143-151.
[15]董鑫, 汪海岩. 术前乳酸脱氢酶/白蛋白比值在进展期胃癌
中的预后分析[J]. 科学技术与工程, 2019, 19(29): 73-76.
[Dong X, Wang HY. Prognosis analysis of preoperative lactatedehydrogenase/
albumin ratio in advanced gastric cancer[J]. Ke
Xue Ji Shu Yu Gong Cheng, 2019, 19(29): 73-76.]
[16] Faloppi L, Scartozzi M, Bianconi M, et al. The role of LDH serum
levels in predicting global outcome in HCC patients treated with
sorafenib: implications for clinical management[J]. BMC Cancer,
2014, 14: 110.
[17] Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: At the bench
and bedside[J]. Semin Cancer Biol, 2019, 59: 125-132.
[18] Manerba M, Di Ianni L, Govoni M, et al. LDH inhibition impacts
on heat shock response and induces senescence of hepatocellular
carcinoma cells[J]. Eur J Pharm Sci, 2017, 105: 91-98.
[19] 翟永贞, 岳阳阳, 丁德平, 等. 血清前白蛋白联合终末期肝病
模型评分评估失代偿期肝硬化患者预后的临床价值[J]. 中
华肝脏病杂志, 2017, 25(7): 533-535. [Zhai YZ, Yue YY, Ding
DP, et al. The value of serum prealbumin combined with MELD
score in predicting the prognosis of patients with decompensated
cirrhosis[J]. Zhonghua Gan Zang Bing Za Zhi, 2017, 25(7):
533-535.]
[20] Fox R, Berhane S, Teng M, et al. Biomarker-based prognosis in
hepatocellular carcinoma: validation and extension of the BALAD
model[J]. Br J Cancer, 2014, 110(8): 2090-2098. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
